Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17366638 | 0.98 | ELANE (0.54) | ELANEPKMPKLRBCL2FGFR1 | |
| SCHEMBL14023517 | 0.96 | ELANE (0.54) | ELANEPKMPKLRBCL2FGFR1 | |
| SCHEMBL14023519 | 0.92 | ELANE (0.50) | ELANEPKMPKLRBCL2FGFR1 | |
| SCHEMBL14023503 | 0.90 | PTGES (0.45) | ELANEPKMPKLRGABRPGABRD | |
| SCHEMBL14023512 | 0.86 | PTGES (0.45) | ELANEPKMPKLRGABRPGABRD | |
| SCHEMBL14023740 | 0.85 | CDC7 (0.45) | ELANEGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL17366637 | 0.84 | AMY1A (0.44) | ELANECLK1NPBWR1MAPTPTGES | |
| SCHEMBL14220601 | 0.82 | CLK1 (0.44) | ELANEPKMPKLRGABRPGABRD | |
| SCHEMBL14023531 | 0.82 | AMY1A (0.44) | ELANECLK1MAPTPTGESCDK5 | |
| SCHEMBL12561669 | 0.82 | ALDH1A1 (0.59) | FGFR1FGFR2CLK1MAPTTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692113-B1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| US-8969372-B2 | Aryl imidazoles and their use as anti-cancer agents | Aptose Boisciences Inc. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969372-B2 | Aryl imidazoles and their use as anti-cancer agents | Aptose Boisciences Inc. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | ELANE 4003/4885PKM 3705/4885PKLR 3235/4885 |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | AHR, CBR3, AADAC | ELANE 4054/4885PKM 3642/4885PKLR 2927/4885 |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | ELANE 4003/4885PKM 3705/4885PKLR 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.